Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.

Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME, Graham DY, Borer JS, Wisniewski LM, Wolski KE, Wang Q, Menon V, Ruschitzka F, Gaffney M, Beckerman B, Berger MF, Bao W, Lincoff AM; PRECISION Trial Investigators.

N Engl J Med. 2016 Dec 29;375(26):2519-29. doi: 10.1056/NEJMoa1611593. Epub 2016 Nov 13.

2.

Carbon monoxide poisoning deaths in the United States, 1999 to 2012.

Sircar K, Clower J, Shin MK, Bailey C, King M, Yip F.

Am J Emerg Med. 2015 Sep;33(9):1140-5. doi: 10.1016/j.ajem.2015.05.002. Epub 2015 May 13.

3.

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).

Bolli GB, Riddle MC, Bergenstal RM, Ziemen M, Sestakauskas K, Goyeau H, Home PD; on behalf of the EDITION 3 study investigators.

Diabetes Obes Metab. 2015 Apr;17(4):386-94. doi: 10.1111/dom.12438. Epub 2015 Feb 12.

4.

National carbon monoxide poisoning surveillance framework and recent estimates.

Iqbal S, Clower JH, King M, Bell J, Yip FY.

Public Health Rep. 2012 Sep-Oct;127(5):486-96.

5.

A review of disaster-related carbon monoxide poisoning: surveillance, epidemiology, and opportunities for prevention.

Iqbal S, Clower JH, Hernandez SA, Damon SA, Yip FY.

Am J Public Health. 2012 Oct;102(10):1957-63. Epub 2012 Aug 16. Review.

6.

Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.

Schumacher HR Jr, Evans RR, Saag KG, Clower J, Jennings W, Weinstein SP, Yancopoulos GD, Wang J, Terkeltaub R.

Arthritis Care Res (Hoboken). 2012 Oct;64(10):1462-70. doi: 10.1002/acr.21690.

7.

The UHMS/CDC carbon monoxide poisoning surveillance program: three-year data.

Hampson NB, Dunn SL, Yip FY, Clower JH, Weaver LK.

Undersea Hyperb Med. 2012 Mar-Apr;39(2):667-85. No abstract available.

PMID:
22530450
8.

Partnering with a medical specialty society to perform online public health surveillance.

Hampson NB, Bell J, Clower JH, Dunn SL, Weaver LK.

Undersea Hyperb Med. 2012 Mar-Apr;39(2):647-55.

PMID:
22530448
9.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, Rosenstock J, Endahl LA, Francisco AM, Hollander P; NN1250-3582 (BEGIN BB T2D) Trial Investigators.

Lancet. 2012 Apr 21;379(9825):1498-507. doi: 10.1016/S0140-6736(12)60205-0.

PMID:
22521072
10.

Residential carbon monoxide alarm prevalence and ordinance awareness.

Iqbal S, Clower JH, Saha S, Boehmer TK, Mattson C, Yip FY, Cobb RD, Flanders WD.

J Public Health Manag Pract. 2012 May-Jun;18(3):272-8. doi: 10.1097/PHH.0b013e318221b1d1.

PMID:
22473121
11.

Recipients of hyperbaric oxygen treatment for carbon monoxide poisoning and exposure circumstances.

Clower JH, Hampson NB, Iqbal S, Yip FY.

Am J Emerg Med. 2012 Jul;30(6):846-51. doi: 10.1016/j.ajem.2011.05.028. Epub 2011 Aug 19.

PMID:
21855265
12.

Hospital burden of unintentional carbon monoxide poisoning in the United States, 2007.

Iqbal S, Law HZ, Clower JH, Yip FY, Elixhauser A.

Am J Emerg Med. 2012 Jun;30(5):657-64. doi: 10.1016/j.ajem.2011.03.003. Epub 2011 May 12.

PMID:
21570230
13.

Carbon monoxide poisoning after an ice storm in Kentucky, 2009.

Lutterloh EC, Iqbal S, Clower JH, Spiller HA, Riggs MA, Sugg TJ, Humbaugh KE, Cadwell BL, Thoroughman DA.

Public Health Rep. 2011 May-Jun;126 Suppl 1:108-15.

14.

Carbon monoxide-related hospitalizations in the U.S.: evaluation of a web-based query system for public health surveillance.

Iqbal S, Clower JH, Boehmer TK, Yip FY, Garbe P.

Public Health Rep. 2010 May-Jun;125(3):423-32.

15.

Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial.

Pattzi HM, Pitale S, Alpizar M, Bennett C, O'Farrell AM, Li J, Cherrington JM, Guler HP; PHX1149-PROT202 Study Group.

Diabetes Obes Metab. 2010 Apr;12(4):348-55. doi: 10.1111/j.1463-1326.2010.01195.x.

PMID:
20380656
16.

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.

Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA; ACCOMPLISH Trial investigators.

Lancet. 2010 Apr 3;375(9721):1173-81. doi: 10.1016/S0140-6736(09)62100-0. Epub 2010 Feb 18.

PMID:
20170948
17.

Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial.

Chrysant SG, Neutel JM, Ferdinand KC; INCLUSIVE investigators.

J Natl Med Assoc. 2009 Apr;101(4):300-7.

PMID:
19397219
18.

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.

Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ; ACCOMPLISH Trial Investigators.

N Engl J Med. 2008 Dec 4;359(23):2417-28. doi: 10.1056/NEJMoa0806182.

19.

Glaucoma detection in Florida.

Frydman JE, Clower JW, Fulghum JE, Hester MW.

JAMA. 1966 Dec 19;198(12):1237-40. No abstract available.

PMID:
5953510
20.

Irregularities of Bowman's membrane.

Kaufman HE, Clower JW.

Am J Ophthalmol. 1966 Feb;61(2):227-30. No abstract available.

PMID:
5904010

Supplemental Content

Loading ...
Support Center